Posttransplant gilteritinib maintenance therapy may boost survival and reduce relapse in relapsed FLT3-mutated acute myeloid leukemia (AML), but larger trials are still needed.
Andrea Eleazar, MHS
Advertisement
Andrea Eleazar, MHS, is an assistant editor for Targeted Oncology, with interests in noncommunicable diseases, health equity research, and global health. Eleazar holds a Master of Health Science in Epidemiology from the Johns Hopkins Bloomberg School of Public Health, as well as a BS in Public Health and certificate in Writing & Publishing from Drexel University.
Articles by Andrea Eleazar, MHS
Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia.
A study reveals a U-shaped relationship between BMI and CAR T-cell therapy outcomes in multiple myeloma (MM), highlighting the impact of overweight status on efficacy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
2
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains
3
Study Finds Flaw in Method for Key Oncology Value-Based Care Model
4
Defunding Co-Payment Assistance Disrupted nAMD Care
5